| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MYH6; MYH7; MYHC; MYHCA; MYHCB; Myosin heavy chain 6; Myosin heavy chain; Myosin-6;;Myosin heavy chain 6/7 |
| WB Predicted band size | Calculated MW: 223,224 kDa ; Observed MW: 224 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Myosin heavy chain 6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于GRIK2抗体的3篇参考文献的简要概述：
---
1. **文献名称**: *"GluK2 antibody reveals the dynamic expression of kainate receptors in the developing rodent brain"*
**作者**: Schiffer, H. H., Swanson, G. T., & Heinemann, S. F.
**摘要**: 该研究利用GRIK2(GluK2)特异性抗体，系统分析了红藻氨酸受体在小鼠发育过程中的表达动态。通过免疫组化和Western blot，发现GluK2在出生后海马体和皮层中表达显著上调，提示其在神经发育中的潜在作用。
---
2. **文献名称**: *"Altered GRIK2 antibody reactivity in schizophrenia: a post-mortem brain study"*
**作者**: Beneyto, M., & Meador-Woodruff, J. H.
**摘要**: 研究通过免疫组织化学技术，检测精神分裂症患者前额叶皮层中GRIK2蛋白的表达水平。结果显示患者组GRIK2抗体标记的神经元密度降低，表明谷氨酸能信号异常可能与疾病病理相关。
---
3. **文献名称**: *"Antibody validation and functional analysis of GRIK2 in a mouse model of epilepsy"*
**作者**: Contractor, A., Mulle, C., & Swanson, G. T.
**摘要**: 该文献验证了GRIK2抗体的特异性(通过基因敲除小鼠模型)，并发现癫痫模型中GRIK2蛋白在突触后膜的聚集增加，提示其参与癫痫发作的突触可塑性调控。
---
这些文献涵盖了GRIK2抗体在发育生物学、精神疾病研究和癫痫模型中的应用，反映了其在基础研究与临床关联中的多样性。如需具体文献来源，建议通过PubMed或Google Scholar检索标题或作者名获取全文。
The GRIK2 antibody targets the glutamate ionotropic receptor kainate type subunit 2 (GRIK2), a protein encoded by the *GRIK2* gene in humans. GRIK2. also known as GluK2. is a critical component of kainate receptors, a subclass of ionotropic glutamate receptors (iGluRs) that mediate excitatory neurotransmission in the central nervous system. These receptors function as ligand-gated ion channels, activated by glutamate, the primary excitatory neurotransmitter. Kainate receptors, including those containing GluK2 subunits, are involved in synaptic plasticity, neuronal development, and modulation of neurotransmitter release. The GRIK2 subunit forms tetrameric receptors, often assembling with other subunits (e.g., GluK5) to influence receptor properties such as calcium permeability and ligand affinity.
GRIK2 is predominantly expressed in the hippocampus, cerebellum, and cerebral cortex, highlighting its role in cognitive functions, motor coordination, and memory formation. Dysregulation of GRIK2 has been implicated in neurological and psychiatric disorders, including epilepsy, schizophrenia, and autism spectrum disorders. Genetic variations in *GRIK2* are also associated with altered receptor function, potentially contributing to disease pathophysiology.
GRIK2 antibodies are essential tools for studying the expression, localization, and functional roles of GluK2-containing receptors in both healthy and diseased states. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate receptor distribution in tissues or cellular models. Additionally, these antibodies aid in exploring the therapeutic potential of targeting kainate receptors in neurological conditions.
×
